Skip to content
Protas logo Protas logo Protas logo
  • What we do
  • Cantata New!
  • Our people
  • News & stories
  • Work at Protas
  • Get in touch Contact Get in touch Contact
Protas logo
  • What we do
  • Cantata
  • Our people
  • News & stories
  • Work at Protas
  • Search
News & Stories

Apollo Therapeutics and Protas partner to advance therapeutic programmes

  • News
September 7, 2023

Share

Protas announces a new partnership with UK-based portfolio biopharmaceutical company Apollo Therapeutics to advance its portfolio of therapeutic programmes.

The Apollo Therapeutics logo on a green background
Apollo Therapeutics is a portfolio biopharmaceutical company

Protas will provide expertise in designing streamlined clinical trials for a range of Apollo’s broad and diversified drug development programmes, in order to produce high-quality, robust and definitive clinical outcomes.

Apollo’s portfolio includes potential new treatments for some of the most common disease areas and has rich potential to result in meaningful treatment options for patients. This makes Apollo an ideal partner in Protas’ mission of reducing the burden of common diseases worldwide.

Prof Sir Martin Landray, CEO of Protas, said:

“We are thrilled to be supporting Apollo with their ambitious and promising portfolio of therapies.

“Protas was set up to transform the way that trials are designed and delivered globally, to encourage the development of more effective treatments for common diseases.

“Collaborations with innovative companies like Apollo are vital in making this change possible, and we are looking forward to working with the team on this shared vision.”

Dr Richard Mason, CEO of Apollo Therapeutics, said:

“This partnership with Protas will be hugely beneficial to our therapeutic aims and ability to develop those portfolio programmes focusing on large chronic disorders.

“With Protas’ experience, expertise and integrated approach, we aim to progress our portfolio, with the ultimate goal of providing innovative healthcare to as many patients as possible.”

Protas logo
  • What we do
  • Cantata
  • Our people
  • News & stories
  • Work at Protas
  • Get in touch
  • Engagement with public contributors
  • Website privacy policy
  • Modern slavery statement
  • Terms of use
  • Tenders


© Protas 2025 Managed by Webheads
  • Follow us